tiprankstipranks
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
US Market
KYMR
Kymera Therapeutics
RESEARCH TOOLSreports
Want to see KYMR full AI Analyst Report?

Kymera Therapeutics (KYMR) Stock News & Sentiment

429 Followers
Reaffirming Buy: Kymera’s Protein Degradation Platform and KT-621 Pipeline Advance Underpin Long-Term Value
Premium
Ratings
Reaffirming Buy: Kymera’s Protein Degradation Platform and KT-621 Pipeline Advance Underpin Long-Term Value
23d ago
KYMR
Kymera Therapeutics Updates Bylaws on Federal Securities Litigation
Premium
Company Announcements
Kymera Therapeutics Updates Bylaws on Federal Securities Litigation
1M ago
8K
KYMR
Kymera: Expanding Degrader Pipeline and Early Clinical Validation Support Buy Rating and Favorable Risk-Reward
Premium
Ratings
Kymera: Expanding Degrader Pipeline and Early Clinical Validation Support Buy Rating and Favorable Risk-Reward
2M ago
KYMR
Kymera Therapeutics Signals Strong Momentum In Earnings Call
Premium
Company Announcements
Kymera Therapeutics Signals Strong Momentum In Earnings Call
2M ago
KYMR
Kymera’s KT-579 Enters First-in-Human Testing: What Early Trial Progress Means for Investors
Premium
Company Announcements
Kymera’s KT-579 Enters First-in-Human Testing: What Early Trial Progress Means for Investors
2M ago
KYMR
Kymera Therapeutics: Advancing Differentiated Oral Immunology Assets with Multi-Indication Runway Through 2029
Premium
Ratings
Kymera Therapeutics: Advancing Differentiated Oral Immunology Assets with Multi-Indication Runway Through 2029
2M ago
KYMR
Kymera Therapeutics Establishes New $500 Million ATM Program
Premium
Company Announcements
Kymera Therapeutics Establishes New $500 Million ATM Program
2M ago
8K
KYMR
More KYMR News >

KYMR News on the Web

Insider Sell: Noah Goodman Sells Shares of Kymera Therapeutics Inc (KYMR)
GuruFocus News
Neutral
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug
Zacks
Bullish
FDA grants fast track designation to Kymera Therapeutics KT-621
TipRanks News
Bullish
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
Zacks
Bullish
Reaffirming Buy: Kymera’s Protein Degradation Platform and KT-621 Pipeline Advance Underpin Long-Term Value
TipRanks News
Bullish
Kymera Therapeutics announces Gilead option exercise to license KT-200
TipRanks News
Bullish
Why Kymera Therapeutics Shares Are Sinking Today
TipRanks News
Neutral
Kymera Therapeutics presents results from BroADen Phase 1b AD trial of KT-621
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
KYMR
Sector Average
Media Buzz
This Week2 articles
Weekly Average2.25 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is KYMR’s Media Buzz Sentiment?
2 articles about KYMR were published this week. In an average week, 2.25 articles are published.
    What is KYMR’s weekly average amount of articles?
    In an average week, 2.25 articles about KYMR are published.
      What is KYMR’s News Sentiment?
      100% of articles about KYMR were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week